Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DF 2001

Next Previous
Drug Profile

DF 2001

Alternative Names: BMS-986357; CC-96191; DF-2001

Latest Information Update: 21 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dragonfly Therapeutics
  • Developer Celgene Corporation
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 14 Apr 2025 Celgene terminates a Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in Canada (IV) due to change in business objectives(NCT04789655)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(In the elderly, Second-line therapy or greater, In adults) in France (IV)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(In the elderly, Second-line therapy or greater, In adults) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top